CTLA4 and neoplasm: Another study tested combination therapy of anti-CTLA-4 with RT and demonstrated that this strategy not only depleted Treg (by anti-CTLA-4) but also promoted the diversity of TCR repertoire of TILs (by RT), resulting in potent anti-tumor responses.